Michael John Gill

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6485364/publications.pdf

Version: 2024-02-01

174	11,361	41344	30087
papers	citations	49	103
		h-index	g-index

175	175	175	11876
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet, The, 2002, 360, 119-129.	13.7	1,415
2	Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada. PLoS ONE, 2013, 8, e81355.	2.5	1,111
3	Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival. New England Journal of Medicine, 2009, 360, 1815-1826.	27.0	986
4	Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV,the, 2017, 4, e349-e356.	4.7	805
5	Risk of Anal Cancer in HIV-Infected and HIV-Uninfected Individuals in North America. Clinical Infectious Diseases, 2012, 54, 1026-1034.	5.8	453
6	A Comparison of Two Regimens for the Treatment ofMycobacterium aviumComplex Bacteremia in AIDS: Rifabutin, Ethambutol, and Clarithromycin versus Rifampin, Ethambutol, Clofazimine, and Ciprofloxacin. New England Journal of Medicine, 1996, 335, 377-384.	27.0	304
7	Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet, The, 2004, 364, 51-62.	13.7	303
8	Cumulative Incidence of Cancer Among Persons With HIV in North America. Annals of Internal Medicine, 2015, 163, 507-518.	3.9	271
9	Late Presentation for Human Immunodeficiency Virus Care in the United States and Canada. Clinical Infectious Diseases, 2010, 50, 1512-1520.	5.8	187
10	Invasive Cervical Cancer Risk Among HIV-Infected Women. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 405-413.	2.1	184
11	Cohort Profile: The North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). International Journal of Epidemiology, 2007, 36, 294-301.	1.9	176
12	Human immunodeficiency virus type 1 Nef protein mediates neural cell death: a neurotoxic role for IP-10. Virology, 2004, 329, 302-318.	2.4	158
13	Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor. Aids, 1998, 12, 2161-2167.	2.2	142
14	End-Stage Renal Disease Among HIV-Infected Adults in North America. Clinical Infectious Diseases, 2015, 60, 941-949.	5.8	142
15	Impact of Risk Factors for Specific Causes of Death in the First and Subsequent Years of Antiretroviral Therapy Among HIV-Infected Patients. Clinical Infectious Diseases, 2014, 59, 287-297.	5.8	136
16	Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: Protease inhibitorÃ¢Â€Â“mediated neurotoxicity. Annals of Neurology, 2006, 59, 816-824.	5.3	131
17	Multimorbidity Among Persons Living with Human Immunodeficiency Virus in the United States. Clinical Infectious Diseases, 2018, 66, 1230-1238.	5.8	131
18	HIV Infection of the Central Nervous System: Clinical Features and Neuropathogenesis. Neurologic Clinics, 2008, 26, 799-819.	1.8	127

#	Article	IF	Citations
19	Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000â€“2010. Journal of Infectious Diseases, 2016, 214, 862-872.	4.0	116
20	Compartmentalization of the gut viral reservoir in HIV-1 infected patients. Retrovirology, 2007, 4, 87.	2.0	106
21	Virologic and immunologic response to HAART, by age and regimen class. Aids, 2010, 24, 2469-2479.	2.2	92
22	Trends and Disparities in Antiretroviral Therapy Initiation and Virologic Suppression Among Newly Treatment-Eligible HIV-Infected Individuals in North America, 2001â€“2009. Clinical Infectious Diseases, 2013, 56, 1174-1182.	5.8	90
23	Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy. PLoS ONE, 2016, 11, e0160460.	2.5	86
24	Evaluation of brief screening tools for neurocognitive impairment in HIV/AIDS. Aids, 2013, 27, 2385-2401.	2.2	82
25	Cytotoxic CD4+ T cells use granulysin to kill Cryptococcus neoformans, and activation of this pathway is defective in HIV patients. Blood, 2007, 109, 2049-2057.	1.4	79
26	Changes Over Time in Risk of Initial Virological Failure of Combination Antiretroviral Therapy. Archives of Internal Medicine, 2006, 166, 521.	3.8	77
27	Incidence and risk factors of HPV-related and HPV-unrelated Head and Neck Squamous Cell Carcinoma in HIV-infected individuals. Oral Oncology, 2014, 50, 1169-1176.	1.5	77
28	The persisting burden of invasive pneumococcal disease in HIV patients: an observational cohort study. BMC Infectious Diseases, 2011, 11, 314.	2.9	76
29	Accelerated replicative senescence of the peripheral immune system induced by HIV infection. Aids, 2000, 14, 771-780.	2.2	75
30	CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virusâ€“Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC). Clinical Infectious Diseases, 2017, 65, 959-966.	5.8	75
31	CD4 count at presentation for HIV care in the United States and Canada: Are those over 50 years more likely to have a delayed presentation?. AIDS Research and Therapy, 2010, 7, 45.	1.7	73
32	Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002â€“2009. Aids, 2013, 27, 803-813.	2.2	70
33	Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients. PLoS ONE, 2016, 11, e0148231.	2.5	70
34	Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. Aids, 2009, 23, 1689-1699.	2.2	69
35	Cancer-Attributable Mortality Among People With Treated Human Immunodeficiency Virus Infection in North America. Clinical Infectious Diseases, 2017, 65, 636-643.	5.8	67
36	The Direct Medical Costs of Late Presentation (<mml:math) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 82 Td (xmlns:mml="http://www.w3.org 15-Year Period. AIDS Research and Treatment, 2012, 2012, 1-8.	0.7	65

#	Article	IF	Citations
37	Disparities in the Quality of HIV Care When Using US Department of Health and Human Services Indicators. Clinical Infectious Diseases, 2014, 58, 1185-1189.	5.8	65
38	How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World?. Clinical Infectious Diseases, 2016, 62, 919-926.	5.8	65
39	Cohort Profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). International Journal of Epidemiology, 2014, 43, 691-702.	1.9	64
40	HIV Infection, Immunosuppression, and Age at Diagnosis of Non-AIDS-Defining Cancers. Clinical Infectious Diseases, 2016, 64, ciw764.	5.8	63
41	Growth hormone prevents human immunodeficiency virusâ€“induced neuronal p53 expression. Annals of Neurology, 2003, 54, 605-614.	5.3	60
42	Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras. Clinical Infectious Diseases, 2016, 63, ciw531.	5.8	60
43	Reduced antiretroviral drug efficacy and concentration in HIV-infected microglia contributes to viral persistence in brain. Retrovirology, 2017, 14, 47.	2.0	57
44	Central nervous system penetration effectiveness of antiretroviral drugs and neuropsychological impairment in the Ontario HIV Treatment Network Cohort Study. Journal of NeuroVirology, 2016, 22, 349-357.	2.1	56
45	Trends in Multidrug Treatment Failure and Subsequent Mortality among Antiretroviral Therapyâ€“Experienced Patients with HIV Infection in North America. Clinical Infectious Diseases, 2009, 49, 1582-1590.	5.8	55
46	Hepatitis C virus co-infection increases neurocognitive impairment severity and risk of death in treated HIV/AIDS. Journal of the Neurological Sciences, 2012, 312, 45-51.	0.6	55
47	Comparison of the RealTime HIV-1, COBAS TaqMan 48 v1.0, Easy Q v1.2, and Versant v3.0 assays for Determination of HIV-1 Viral Loads in a Cohort of Canadian Patients with Diverse HIV Subtype Infections. Journal of Clinical Microbiology, 2011, 49, 118-124.	3.9	53
48	Intimate Partner Violence and HIV: A Review. Current HIV/AIDS Reports, 2013, 10, 380-389.	3.1	52
49	Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study. Clinical Infectious Diseases, 2016, 62, 1571-1577.	5.8	52
50	Patients presenting with AIDS in the HAART era: a collaborative cohort analysis. Aids, 2008, 22, 2461-2469.	2.2	51
51	Changing Epidemiology and Risk Factors for Gastrointestinal Non-Hodgkin's Lymphoma in a North American Population: Population-Based Study. American Journal of Gastroenterology, 2008, 103, 1762-1769.	0.4	48
52	Prevalence, clinical associations, and impact of intimate partner violence among <scp>HIV</scp>â€infected gay and bisexual men: a populationâ€based study. HIV Medicine, 2013, 14, 293-302.	2.2	48
53	Domestic Violence Screening: Prevalence and Outcomes in a Canadian HIV Population. AIDS Patient Care and STDs, 2010, 24, 763-770.	2.5	47
54	Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study. Lancet HIV,the, 2019, 6, e240-e249.	4.7	46

#	Article	IF	Citations
55	Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients. Aids, 1998, 12, F103-F109.	2.2	45
56	Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study. Clinical Infectious Diseases, 2017, 65, 1316-1326.	5.8	44
57	Rhodococcus equiâ€"An easily missed opportunistic pathogen. Scandinavian Journal of Infectious Diseases, 1991, 23, 1-6.	1.5	43
58	HIV-1 viral diversity and its implications for viral load testing: review of current platforms. International Journal of Infectious Diseases, 2011, 15, e661-e670.	3.3	43
59	Hepatitis C Viremia and the Risk of Chronic Kidney Disease in HIV-Infected Individuals. Journal of Infectious Diseases, 2013, 208, 1240-1249.	4.0	43
60	The Impact of Non-Antiretroviral Polypharmacy on the Continuity of Antiretroviral Therapy (ART) Among HIV Patients. AIDS Patient Care and STDs, 2016, 30, 11-17.	2.5	43
61	HIV dementia patients exhibit reduced viral neutralization and increased envelope sequence diversity in blood and brain. Aids, 2002, 16, 1905-1914.	2.2	39
62	Plasma microRNA profiling predicts HIV-associated neurocognitive disorder. Aids, 2016, 30, 2021-2031.	2.2	38
63	Active Immunization of Patients with HIV Infection: A Study of the Effect of VaxSyn, a Recombinant HIV Envelope Subunit Vaccine, on Progression of Immunodeficiency. AIDS Research and Human Retroviruses, 1998, 14, 483-490.	1.1	37
64	Inflammation and epithelial cell injury in AIDS enteropathy: involvement of endoplasmic reticulum stress. FASEB Journal, 2011, 25, 2211-2220.	0.5	37
65	First occurrence of diabetes, chronic kidney disease, and hypertension among North American HIV-infected adults, 2000-2013. Clinical Infectious Diseases, 2017, 64, ciw804.	5.8	37
66	Herpes simplex virus infection of the hand. Journal of the American Academy of Dermatology, 1990, 22, 111-116.	1.2	35
67	Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. International Journal of Epidemiology, 2012, 41, 1807-1820.	1.9	34
68	Risk Factors for Tuberculosis After Highly Active Antiretroviral Therapy Initiation in the United States and Canada: Implications for Tuberculosis Screening. Journal of Infectious Diseases, 2011, 204, 893-901.	4.0	33
69	Life-Expectancy Disparities Among Adults With HIV in the United States and Canada: The Impact of a Reduction in Drug- and Alcohol-Related Deaths Using the Lives Saved Simulation Model. American Journal of Epidemiology, 2019, 188, 2097-2109.	3.4	32
70	Gastrointestinal tissue cultures for HIV in HIV-infected/AIDS patients. Aids, 1992, 6, 553-556.	2.2	28
71	Influence of Geographical Origin and Ethnicity on Mortality in Patients on Antiretroviral Therapy in Canada, Europe, and the United States. Clinical Infectious Diseases, 2013, 56, 1800-1809.	5.8	28
72	HIV-associated sensory polyneuropathy and neuronal injury are associated with miRNAâ€“455-3p induction. JCI Insight, 2018, 3, .	5.0	28

#	Article	IF	Citations
73	Association of Immunosuppression and Human Immunodeficiency Virus (HIV) Viremia With Anal Cancer Risk in Persons Living With HIV in the United States and Canada. Clinical Infectious Diseases, 2020, 70, 1176-1185.	5.8	27
74	Lifetime antiretroviral exposure and neurocognitive impairment in HIV. Journal of NeuroVirology, 2020, 26, 743-753.	2.1	26
75	Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015. JAMA Network Open, 2021, 4, e2037512.	5.9	26
76	CD4/CD8 Ratio and Cancer Risk Among Adults With HIV. Journal of the National Cancer Institute, 2022, 114, 854-862.	6.3	26
77	Does In Vitro Susceptibility to Rifabutin and Ethambutol Predict the Response to Treatment ofMycobacterium aviumComplex Bacteremia with Rifabutin, Ethambutol, and Clarithromycin?. Clinical Infectious Diseases, 1998, 27, 1401-1405.	5.8	25
78	Antiretroviral Medication Adherence and Persistence with Respect to Adherence Tool Usage. AIDS Patient Care and STDs, 2000, 14, 351-358.	2.5	25
79	The five-year impact of an evolving global epidemic, changing migration patterns, and policy changes in a regional Canadian HIV population. Health Policy, 2009, 90, 296-302.	3.0	25
80	Impact of current antiretroviral therapies on neuroAIDS. Expert Review of Anti-Infective Therapy, 2011, 9, 371-374.	4.4	25
81	Avascular necrosis in HIV infection. Aids, 1999, 13, 1997.	2.2	25
82	Virological characteristics of occult hepatitis B virus in a North American cohort of human immunodeficiency virus type 1-positive patients on dual active anti-HBV/HIV therapy. Journal of Clinical Virology, 2014, 60, 347-353.	3.1	23
83	Role of viral evolutionary rate in HIV-1 disease progression in a linked cohort. Retrovirology, 2005, 2, 41.	2.0	22
84	Timing of Antiretroviral Therapy Initiation and Risk of Cancer Among Persons Living With Human Immunodeficiency Virus. Clinical Infectious Diseases, 2021, 72, 1900-1909.	5.8	22
85	Associations between Depressive Symptomatology and Neurocognitive Impairment in HIV/AIDS. Canadian Journal of Psychiatry, 2018, 63, 329-336.	1.9	21
86	Neuropsychiatric disorders in HIV infection: impact of diagnosis on economic costs of care. Aids, 2006, 20, 2005-2009.	2.2	20
87	Evaluating the Impact of Functional Genetic Variation on HIV-1 Control. Journal of Infectious Diseases, 2017, 216, 1063-1069.	4.0	20
88	Short Communication:Identification of a Novel HIV Type 1 Subtype H/J Recombinant in Canada with Discordant HIV Viral Load (RNA) Values in Three Different Commercial Assays. AIDS Research and Human Retroviruses, 2007, 23, 1309-1313.	1.1	19
89	Comparative Effectiveness of Initial Antiretroviral Therapy Regimens. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 58, 253-260.	2.1	19
90	Implementing an Intimate Partner Violence (IPV) Screening Protocol in HIV Care. AIDS Patient Care and STDs, 2015, 29, 133-141.	2.5	19

#	Article	IF	Citations
91	Neurotoxicity of acyclovir in end stage renal disease. Journal of Antimicrobial Chemotherapy, 1990, 25, 300-300.	3.0	18
92	Absence of an Association Between Enteric Parasites in the Manifestations and Pathogenesis of HIV Enteropathy in Gay Men. Scandinavian Journal of Infectious Diseases, 1992, 24, 567-575.	1.5	18
93	Does short-term virologic failure translate to clinical events in antiretroviral-naÃ¯ve patients initiating antiretroviral therapy in clinical practice?. Aids, 2008, 22, 2481-2492.	2.2	18
94	Brief Report: Cutaneous Melanoma Risk Among People With HIV in the United States and Canada. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 499-504.	2.1	17
95	A potentially preventable case of serious influenza infection in a pregnant patient. Cmaj, 2007, 177, 851-853.	2.0	16
96	Higher levels of Zidovudine resistant HIV in the colon compared to blood and other gastrointestinal compartments in HIV infection. Retrovirology, 2010, 7, 74.	2.0	16
97	Survival Outcomes and Effect of Early vs. Deferred cART Among HIV-Infected Patients Diagnosed at the Time of an AIDS-Defining Event: A Cohort Analysis. PLoS ONE, 2011, 6, e26009.	2.5	16
98	Uptake of Combination Antiretroviral Therapy and HIV Disease Progression According to Geographical Origin in Seroconverters in Europe, Canada, and Australia. Clinical Infectious Diseases, 2012, 54, 111-118.	5.8	16
99	HIV misdiagnosis: A root cause analysis leading to improvements in HIV diagnosis and patient care. Journal of Clinical Virology, 2017, 96, 84-88.	3.1	16
100	Increasing incidence of syphilis among patients engaged in HIV care in Alberta, Canada: a retrospective clinic-based cohort study. BMC Infectious Diseases, 2018, 18, 125.	2.9	16
101	A retrospective study of the clinical features of new syphilis infections in an HIV-positive cohort in Alberta, Canada. BMJ Open, 2018, 8, e021544.	1.9	16
102	Empiric neurocognitive performance profile discovery and interpretation in HIV infection. Journal of NeuroVirology, 2019, 25, 72-84.	2.1	16
103	Machine learning models reveal neurocognitive impairment type and prevalence are associated with distinct variables in HIV/AIDS. Journal of NeuroVirology, 2020, 26, 41-51.	2.1	16
104	Full-Length HIV Type 1 Genome Analysis Showing Evidence for HIV Type 1 Transmission from a Nonprogressor to Two Recipients Who Progressed to AIDS. AIDS Research and Human Retroviruses, 2005, 21, 575-579.	1.1	15
105	Clinical outcomes and immune benefits of anti-epileptic drug therapy in HIV/AIDS. BMC Neurology, 2010, 10, 44.	1.8	15
106	Adverse Health Effects for Individuals Who Move Between HIV Care Centers. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, 51-54.	2.1	15
107	The Cost of Antiretroviral Drug Resistance in HIV-Positive Patients. Antiviral Therapy, 2014, 19, 341-348.	1.0	14
108	Tobacco Smoking Is Not Associated With Accelerated Liver Disease in Human Immunodeficiency Virus-Hepatitis C Coinfection: A Longitudinal Cohort Analysis. Open Forum Infectious Diseases, 2016, 3, ofw050.	0.9	14

#	Article	IF	Citations
109	An approach to conference selection and evaluation: advice to avoid â€œpredatoryâ€•conferences. Scientometrics, 2019, 118, 687-698.	3.0	14
110	Improved Survival and Reduced Clinical Progression in HIV-Infected Patients with Advanced Disease Treated with Saquinavir plus Zalcitabine. Antiviral Therapy, 1998, 3, 33-42.	1.0	14
111	Decision making under explicit risk is impaired in individuals with human immunodeficiency virus (HIV). Journal of Clinical and Experimental Neuropsychology, 2015, 37, 733-750.	1.3	13
112	Combating the HIV reservoirs. Biotechnology and Genetic Engineering Reviews, 2018, 34, 76-89.	6.2	13
113	Efavirenz dosing in patients receiving continuous ambulatory peritoneal dialysis. Aids, 2000, 14, 1062.	2.2	13
114	Childhood Lymphadenitis in a Harsh Northern Climate due to Atypical Mycobacteria. Scandinavian Journal of Infectious Diseases, 1987, 19, 77-83.	1.5	12
115	Z-FA-FMK as a novel potent inhibitor of reovirus pathogenesis and oncolysis in vivo. Antiviral Therapy, 2010, 15, 897-905.	1.0	12
116	Managing HIV infection in patients older than 50 years. Cmaj, 2018, 190, E1253-E1258.	2.0	12
117	Cytomegalovirus Disease in HIV Infection: Twenty Years of a Regional Population's Experience. Clinical Infectious Diseases, 2006, 42, 1808-1809.	5.8	11
118	Discrepancies in Assignment of Subtype/Recombinant Forms by Genotyping Programs for HIV Type 1 Drug Resistance Testing May Falsely Predict Superinfection. AIDS Research and Human Retroviruses, 2008, 24, 995-1002.	1.1	11
119	Montreal Cognitive Assessment Performance in HIV/AIDS: Impact of Systemic Factors. Canadian Journal of Neurological Sciences, 2016, 43, 157-162.	0.5	11
120	Lymphocyte Membrane Modifications Induced by HIV Infection.. Tohoku Journal of Experimental Medicine, 1994, 173, 115-131.	1.2	10
121	An avoidable transmission of HIV from mother to child. Cmaj, 2011, 183, 690-692.	2.0	10
122	Understanding the delay in starting antiretroviral therapy despite recent guidelines for HIV patients retained in care. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2017, 29, 564-569.	1.2	10
123	Five-Year Mortality for Adults Entering Human Immunodeficiency Virus Care Under Universal Early Treatment Compared With the General US Population. Clinical Infectious Diseases, 2022, 75, 867-874.	5.8	10
124	Impact of Practice Changes on an Antiretroviral Budget in an HIV Care Program. Disease Management and Health Outcomes, 2005, 13, 209-217.	0.4	9
125	Participation in HIV Research: The Importance of Clinic Contact Factors. AIDS Patient Care and STDs, 2008, 22, 619-625.	2.5	9
126	Increasing HIV Subtype Diversity in Canadian-Born Patients Living in Southern Alberta, Canada. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, e27-e29.	2.1	9

#	Article	IF	Citations
127	Missing Data on the Estimation of the Prevalence of Accumulated Human Immunodeficiency Virus Drug Resistance in Patients Treated With Antiretroviral Drugs in North America. American Journal of Epidemiology, 2011, 174, 727-735.	3.4	9
128	An Emerging Concernâ€"High Rates of Frailty among Middle-aged and Older Individuals Living with HIV. Canadian Geriatrics Journal, 2019, 22, 190-198.	1.2	9
129	A picture is worth a thousand words: maps of HIV indicators to inform research, programs, and policy from NAâ€ACCORD and CCASAnet clinical cohorts. Journal of the International AIDS Society, 2016, 19, 20707.	3.0	8
130	Evaluating medical conferences: the emerging need for a quality metric. Scientometrics, 2020, 122, 759-764.	3.0	8
131	Determinants of risk-taking in HIV-associated neurocognitive disorders.. Neuropsychology, 2017, 31, 798-810.	1.3	8
132	Effect of acyclovir on the uptake of131 I-labelled 1-(2â€²fluoro-2â€²-deoxy-Î²D-D-arabinofuranosyl)-5-Iodouracil in herpes infected cells. Journal of Medical Virology, 1987, 22, 183-188.	5.0	7
133	Comparison of healthcare costs between local and immigrant HIV populations living in Southern Alberta, Canada. Health Policy, 2011, 103, 124-129.	3.0	7
134	Mechanisms by Which Interleukin-12 Corrects Defective NK Cell Anticryptococcal Activity in HIV-Infected Patients. MBio, 2016, 7, .	4.1	7
135	Evaluation of A Phylogenetic Pipeline to Examine Transmission Networks in A Canadian HIV Cohort. Microorganisms, 2020, 8, 196.	3.6	7
136	Gastrointestinal Viral Load and Enteroendocrine Cell Number Are Associated with Altered Survival in HIV-1 Infected Individuals. PLoS ONE, 2013, 8, e75967.	2.5	6
137	Clinical Effectiveness of Integrase Strand Transfer Inhibitorâ€"Based Antiretroviral Regimens Among Adults With Human Immunodeficiency Virus: A Collaboration of Cohort Studies in the United States and Canada. Clinical Infectious Diseases, 2020, 73, e1408-e1414.	5.8	6
138	A prognostic model for development of significant liver fibrosis in HIV-hepatitis C co-infection. PLoS ONE, 2017, 12, e0176282.	2.5	6
139	Seroprevalence of Cytomegalovirus,Toxoplasma gondii, Syphilis, and Hepatitis B and C Virus Infections in a Regional Population Seropositive for HIV Infection. Canadian Journal of Infectious Diseases & Medical Microbiology, 1998, 9, 209-214.	0.3	5
140	The Use of Antiretroviral Agents in Patients with Renal Insufficiency. AIDS Patient Care and STDs, 1999, 13, 517-526.	2.5	5
141	Predictors of survival and eradication of Mycobacterium avium complex bacteremia (MAC) in AIDS patients in the Canadian Randomized MAC Treatment Trial. Aids, 1999, 13, 575-582.	2.2	5
142	Similar Challenges with Retention in Care Issues. Clinical Infectious Diseases, 2007, 45, 1527-1527.	5.8	5
143	A Case of Long-Term Seronegative Human Immunodeficiency Virus (HIV) Infection: The Importance of the Humoral Response to HIV. Open Forum Infectious Diseases, 2016, 3, ofv209.	0.9	5
144	Maintaining the continuity of HIV-care records for patients transferring care between centers: challenges, workloads, needs and risks. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2016, 28, 1073-1078.	1.2	5

#	Article	IF	Citations
145	Effect of incident hepatitis C infection on CD4+ cell count and HIV RNA trajectories based on a multinational HIV seroconversion cohort. Aids, 2019, 33, 327-337.	2.2	5
146	Virologic outcomes among adults with HIV using integrase inhibitor-based antiretroviral therapy. Aids, 2022, 36, 277-286.	2.2	5
147	Canadian Expert Panel Recommendations on the Management of CNS Symptoms Related to Efavirenz. Canadian Journal of Infectious Diseases & Medical Microbiology, 2001, 12, 20C-30C.	0.3	4
148	Interpersonal Violence and Its Impact on Persons Living With HIV: A Social Work Response. Journal of HIV/AIDS and Social Services, 2015, 14, 308-318.	0.7	4
149	Identifying Risk of Viral Failure in Treated HIV-Infected Patients Using Different Measures of Adherence: The Antiretroviral Therapy Cohort Collaboration. Journal of Clinical Medicine, 2018, 7, 328.	2.4	4
150	Predictive variables for peripheral neuropathy in treated HIV type 1 infection revealed by machine learning. Aids, 2021, 35, 1785-1793.	2.2	4
151	Reconstructing SARS-CoV-2 infection dynamics through the phylogenetic inference of unsampled sources of infection. PLoS ONE, 2021, 16, e0261422.	2.5	4
152	LIMITATIONS OF OPT-OUT HIV SCREENING AND MOTHERâ€“CHILD HIV TRANSMISSION. American Journal of Public Health, 2010, 100, 388-389.	2.7	3
153	The Impact of Transfer Patients on the Local Cascade of HIV Care Continuum. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 236-240.	2.1	3
154	Healthcare contacts among patients lost to follow-up in HIV care: review of a large regional cohort utilizing electronic health records. International Journal of STD and AIDS, 2017, 28, 1275-1281.	1.1	3
155	HIV diagnosed after 50 years of age. Cmaj, 2020, 192, E255-E255.	2.0	3
156	Schistosoma and Strongyloides screening in migrants initiating HIV Care in Canada: a cross sectional study. BMC Infectious Diseases, 2020, 20, 76.	2.9	3
157	Secular Trends in Breast Cancer Risk Among Women With HIV Initiating ART in North America. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 87, 663-670.	2.1	3
158	Do contemporary antiretrovirals increase the risk of endâ€stage liver disease? Signals from patients starting therapy in the North American AIDS Cohort Collaboration on Research and Design. Pharmacoepidemiology and Drug Safety, 2022, 31, 214-224.	1.9	3
159	Functional relevance of nonsynonymous mutations in the HIV-1 tat gene within an epidemiologically-linked transmission cohort. Virology Journal, 2007, 4, 107.	3.4	2
160	In Defense of Baseline Genotypic Antiretroviral Resistance Testing. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 83, e1-e2.	2.1	2
161	The costs of antiretroviral drug wastage. Aids, 2000, 14, 616-617.	2.2	2
162	HIV-Related Non-Hodgkinâ€™s Lymphoma in Calgary. Canadian Journal of Infectious Diseases & Medical Microbiology, 1996, 7, 115-120.	0.3	1

#	Article	IF	Citations
163	Costing implications of recent treatment interruption studies. Aids, 2006, 20, 2239-2240.	2.2	1
164	The oncology impact of highly active antiretroviral therapy. Journal of Oncology Pharmacy Practice, 2007, 13, 17-25.	0.9	1
165	Myocardial Infarction in HIV-Infected Persons: Time to Focus on the Silent Elephant in the Room?. Clinical Infectious Diseases, 2015, 60, 1424-5.	5.8	1
166	Protecting the health of children moving to Canada. Lancet, The, 2019, 394, 1901-1902.	13.7	1
167	Longitudinal evaluation of risk factors and outcomes of blood stream infections due to Staphylococcus species in persons with HIV: An observational cohort study. EClinicalMedicine, 2021, 31, 100675.	7.1	1
168	Plasma microRNAs are associated with domain-specific cognitive function in people with HIV. Aids, 2021, 35, 1795-1804.	2.2	1
169	Association of the VACS Index with hospitalization among people with HIV in the NA-ACCORD. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, Publish Ahead of Print, 9-18.	2.1	1
170	Transmission of human immunodeficiency virus (HIV) to a family caregiver through a conjunctival blood splash. Infection Control and Hospital Epidemiology, 2020, 41, 742-744.	1.8	1
171	Pooch protease paunch. Lancet, The, 1999, 353, 2078.	13.7	0
172	Mortality in migrants with HIV in western Europe. Lancet HIV,the, 2015, 2, e508-e509.	4.7	0
173	Identification and root cause analysis of aberrant CD4+ cell counts in an HIV cohort: the importance of quality control in changing laboratory procedure. Aids, 2020, 34, 1869-1873.	2.2	0
174	Longitudinal analysis of HIV outcomes for persons living with HIV in non-urban areas in southern Alberta, Canada. Jammi, 2022, 7, 44-53.	0.5	0